DATATRAK International, Inc. (OTCQX: DATA), a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced that it has been awarded a Phase III device study by a new European client, a leading global healthcare supplier.
"We are extremely pleased to welcome this newest European client, as it is particularly rewarding to see long-term relationships flourish into real business opportunities," said Laurence P. Birch, DATATRAK's Chairman and CEO. "DATATRAK confidently marches toward becoming the clinical enterprise solution to safely accelerate every drug, every biologic and every device from concept to cure, and we look forward to delivering eClinical excellence through DATATRAK ONE™ to all of our clients in what continues to be a complex and challenging industry."
DATATRAK eClinical™ is a unified, end-to-end clinical trial solution. By implementing a flexible, permission-based platform, DATATRAK is able to layer modules that support the clinical trial process, from planning to submission as well as integrate with third-party data sources. This unified technology provides one database, one interface and one point of access to all clinical trial activities.
From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech